Cardinal Health, Inc. (CAH)
|Net Income (ttm)||-933.00M|
|Ex-Dividend Date||Sep 30, 2022|
|Day's Range||67.55 - 69.60|
|52-Week Range||45.85 - 72.28|
|Price Target||70.93 (+2.4%)|
|Earnings Date||Nov 7, 2022|
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products... [Read more...]
Financial PerformanceFinancial Statements
According to 20 analysts, the average rating for CAH stock is "Hold." The 12-month stock price forecast is 70.93, which is an increase of 2.37% from the latest price.
We're in the midst of a bear market. That's something investors haven't seen in quite some time.
DUBLIN, Ohio , Sept. 27, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2023 on November 4, prior to the opening of trading on the ...
During times of heightened volatility, an established income stream is undoubtedly a major positive, allowing investors to offset losses in other positions and reap those sweet dividend payouts.
Launching a New, Robust Offering Leveraging Cardinal Health's Advanced Practice Analytics Technology Platform and PayrHealth's Payor Contracting Solution. AUSTIN, Texas , Sept.
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves port...
Cardinal Health stock (NYSE: CAH) has seen a significant 36% rise this year, outperforming the broader S&P500 index, which is down 15%.
Cardinal Health Inc. CAH, -1.23% cut its fiscal first-quarter earnings outlook for its Medical segment, citing ongoing simplification efforts that are expected to result in $25 million in inventory char...
Cardinal Health recently entered an agreement with Elliott Management, agreeing to appoint four director nominees to the board.
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and a diversified product portfolio. However, the cost of products continues to rise.
--Victor Crawford will step down as CEO of Pharmaceutical Segment-- --Debbie Weitzman, President of Pharmaceutical Distribution, named CEO of Pharmaceutical Segment-- DUBLIN, Ohio , Sept. 8, 2022 /PRNew...
Cardinal Health to form new board committee to review business as part of corporate governance moves agreed with Elliott
Cardinal Health Inc. CAH, -0.46% announced a series of measures Tuesday aimed at boosting shareholder value and said activist investor Elliott Investment Management's Steven Barg will join its board. Am...
Adds Four New Independent Directors to the Board Forms New Business Review Committee to Evaluate Portfolio and Operations DUBLIN, Ohio , Sept. 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today a...
Their payouts are likely to continue rising.
One of the U.S.'s three dominant drug-distribution companies, Cardinal Health, is in the crosshairs of an activist investor.
Activist investor Elliott Management has a large position in Cardinal Health Inc. and is seeking a handful of seats on the medical-products distributor's board, according to people familiar with the mat...
The activist investor is seeking a handful of seats on the medical-products distributor's board, according to people familiar with the matter.
Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardinal Health Inc. shares CAH, +1.59% slumped 4.5% in premarket trade Thursday, after the drug distributor missed profit estimates for the second quarte and announced a leadership change. The company ...
Revenue increased 11% to $47.1 billion in the fourth quarter GAAP 1 operating earnings were $36 million in the fourth quarter; GAAP diluted EPS were $0.50 in the fourth quarter Non-GAAP operating earnin...
-- Mike Kaufmann to Step Down as Chief Executive Officer and from Board of Directors -- -- Jason Hollar, Chief Financial Officer, Named Chief Executive Officer -- -- Patricia English to Serve as Interim...